SCHEMBL4093981

SCHEMBL4093981

COC(=S)c1ccc(Cl)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
CYP3A4 P08684 1/20 0.43
ABL1 P00519 1/20 0.43
LMNA P02545 2/20 0.43
NR1I2 O75469 1/20 0.43
TTR P02766 1/20 0.43
PGR P06401 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
MAPT P10636 1/20 0.43
HSPA5 P11021 1/20 0.43
HPGD P15428 1/20 0.43
CBR1 P16152 1/20 0.43
TBXA2R P21731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11631790 0.85 CA1 (0.50) KDM4EALDH1A1TSHRHSD17B10LMNA
SCHEMBL4098055 0.78 IDO1 (0.47) KDM4ETDP1LMNAMAPTHPGD
SCHEMBL32662867 0.77 CA12 (0.67) KDM4EPKMRXFP1ALDH1A1TSHR
SCHEMBL1058422 0.77 CA12 (0.67) KDM4EPKMRXFP1ALDH1A1TSHR
SCHEMBL10374433 0.77 NPC1 (0.61) ALDH1A1TSHRHSD17B10TDP1CYP3A4
SCHEMBL11714480 0.76 ABL1 (0.50) KDM4EALDH1A1TSHRHSD17B10TDP1
SCHEMBL2956458 0.75 HSD17B10 (0.50) KDM4EPKMRXFP1ALDH1A1TSHR
SCHEMBL27827654 0.73 ACMSD (0.56) KDM4EALDH1A1HSD17B10LMNAHSP90AA1
SCHEMBL212176 0.71 LMNA (0.57) KDM4EALDH1A1TSHRHSD17B10LMNA
SCHEMBL31142480 0.71 MAPT (0.59) ALDH1A1TSHRHSD17B10TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-29 US disclosed
EP-1897880-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-03-12 EP disclosed
EP-0530207-A1 IMIDAZOPYRIDINE PAF ANTAGONISTS Pfizer Limited (GB) 1993-03-10 EP disclosed
WO-1991017162-A1 IMIDAZOPYRIDINE PAF ANTAGONISTS PFIZER LIMITED (GB) 1991-11-14 WO disclosed
US-4082770-A ANALGESIC, ANTIPYRETIC, ANTIINFLAMMATORY WARNER-LAMBERT COMPANY (US) 1978-04-04 US disclosed
US-4056526-A ANALGESIC, ANTIPYRETIC, ANTIINFLAMMATORY WARNER-LAMBERT COMPANY (US) 1977-11-01 US disclosed
US-4018793-A ANALGESICS, ANTIINFLAMMATORY, ANTIPYRETICS WARNER-LAMBERT COMPANY (US) 1977-04-19 US disclosed
US-3971814-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS WARNER-LAMBERT COMPANY (US) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029975-A1 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF MIF, CCL2, MSR1 KDM4E 3212/4885PKM 2187/4885RXFP1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.